● Recruiting

Antiviral Therapy for Patients With Liver Cancer After Surgery

Condition: Hepatocellular Carcinoma · Sponsor: Xiangya Hospital of Central South University

PhaseN/A

Planned participants360

Who can joinAll sexes, 18 Years to 65 Years

Healthy volunteersNo

About this study

This is a single-center, prospective, observational, real world study designed to evaluate the effects of peginterferon α-2b(pegabin) combined with nucleoside (acid) analogs (entecavir,ETV tenofovir,TDF tenofovir alafenamide,TAF) on patients after radical surgery for hepatitis B associated hepatocellular carcinoma by collecting data from patients at our hospital

This description comes directly from the study's public registry record.

Talk to the study team

Ledu Zhou, PhD student · 17373120367 · zhould@csu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Xiangya Hospital of Central South University

Changsha, Hunan, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05466565